Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher Sells 4,500 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $6.93, for a total value of $31,185.00. Following the completion of the transaction, the director now owns 69,938 shares in the company, valued at $484,670.34. The trade was a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Duncan Gallagher also recently made the following trade(s):

• On Monday, December 23rd, Duncan Gallagher sold 4,500 shares of Health Catalyst stock. The shares were sold at an average price of $6.98, for a total value of $31,410.00.

Health Catalyst Stock Up 3.8 %

Shares of Health Catalyst stock opened at $7.34 on Friday. The company has a market capitalization of $446.64 million, a P/E ratio of -5.44 and a beta of 1.31. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The business has a 50-day moving average of $7.87 and a two-hundred day moving average of $7.48. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same period in the previous year, the company posted ($0.22) earnings per share. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, equities analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Institutional Investors Weigh In On Health Catalyst

Institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its holdings in shares of Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after purchasing an additional 1,907 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in Health Catalyst by 21.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after buying an additional 2,064 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Health Catalyst by 10.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after acquiring an additional 2,164 shares in the last quarter. Creative Planning boosted its position in Health Catalyst by 13.2% during the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after acquiring an additional 2,486 shares during the last quarter. Finally, Quarry LP grew its stake in shares of Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HCAT has been the subject of a number of research reports. Citigroup lifted their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Royal Bank of Canada increased their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Stephens lifted their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Evercore ISI increased their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.